Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
Guasch
Antonio
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003167:Complement Activation / Q000187:drug effects; D003182:Complement C5 / Q000037:antagonists & inhibitors* / Q000276:immunology; D051056:Complement Inactivating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006457:Hemoglobinuria, Paroxysmal / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D008657:Metabolic Clearance Rate / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; D051056:Complement Inactivating Agents; C481642:eculizumab